TrialScientific reports2024

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.

Satoshi Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.